SMAFIRA_Methods  

Documents (644) JSON TSV

source DB source ID text size updated at # proj. # Ann. updated_at
PubMed 15352652 Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of l 2.26 KB 2019-12-10 3 0
-
PubMed 16163194 Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Despite the advance in supportive care that occurred with t 1.7 KB 2019-12-10 4 0
-
PubMed 16204394 Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting. OBJECTIVE: To determine the prevalence of substandard antiemetic therapy among recently p 1.83 KB 2019-12-10 4 0
-
PubMed 16363682 [SARS coronavirus]. SARS is a new type of infectious pneumonia that emerged in China in November 2002. It spread around the world through an outbreak in Hong Kong in March 2003. Patients were reported 1.14 KB 2015-11-23 4 0
-
PubMed 16670361 Meta-analysis of the use of rescue antiemetics following PONV prophylactic failure with 5-HT3 antagonist/dexamethasone versus single-agent therapies. OBJECTIVE: To assess the use of rescue antiemetic 2.06 KB 2019-12-10 4 0
-
PubMed 16766588 A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. BACKGROUND: This 1.68 KB 2019-12-10 4 0
-
PubMed 10458253 Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. PURPOSE: To evaluate the effect of ondansetron availability on the costs of managing nausea and vomiting. METHO 1.87 KB 2019-12-10 4 0
-
PubMed 16632815 The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery. Based on compa 2.34 KB 2019-12-10 4 0
-
PubMed 16218261 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. Although elderly patients have been reported to be less prone to chemotherapy-induced nausea and vomit 1.8 KB 2019-12-10 4 0
-
PubMed 17026451 Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetog 2.08 KB 2019-12-10 4 0
-